-
LIRP: Light-Controlled RNA Release for Gene Therapy
2026-08-25
The reference study introduces a rationally designed light-inducible RNA-releasing protein that regulates therapeutic protein production at the translation stage, rather than relying only on transcriptional control. In mouse models, LIRP-enabled AAV2 systems supported light-responsive metabolic and retinal gene therapies, while also illustrating the remaining challenges of tissue illumination, dosing, and clinical translation.
-
Ferrostatin-1 (Fer-1): From Assay to Translation
2026-08-25
Ferrostatin-1 (Fer-1) is more than a ferroptosis rescue reagent: it is a mechanistic probe for connecting lipid peroxidation, redox defense, and disease-relevant phenotypes. New ovarian research illustrates how Fer-1 can strengthen causal validation while informing translational study design across cancer biology, neurodegenerative disease models, and oxidative injury.
-
ML385 and the Translational Logic of NRF2 Inhibition
2026-08-24
ML385 offers translational researchers a selective NRF2 inhibitor for dissecting antioxidant adaptation, oxidative stress modulation, and cancer therapeutic resistance. This article connects evidence from non-small cell lung cancer research with emerging ferroptosis and stress-signaling insights in pancreatic cancer while defining practical, evidence-conscious experimental strategies.
-
EZ Cap™ OVA mRNA Workflow for Immune Studies
2026-08-24
EZ Cap™ OVA mRNA provides a defined Ovalbumin mRNA input for antigen-expression assays, immune response immunogen studies, and delivery-platform benchmarking. Its Cap 1 structure and poly(A) tail support reproducible translation while enabling practical comparisons of lipid formulations, expression, and inflammatory readouts.
-
Benzyl-Activated Streptavidin Magnetic Beads
2026-08-23
Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) capture biotinylated molecules through surface streptavidin and enable rapid magnetic separation. Their defined suspension, low surface charge, and reported IgG binding capacity support protein, nucleic acid, interaction, and screening workflows.
-
RNA Pol II Loss Activates Apoptosis Beyond Transcription
2026-08-22
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic signaling pathway triggered by depletion of hypophosphorylated RNA Pol IIA, rather than through passive loss of transcription. Their genetic and pharmacological analyses define the Pol II degradation-dependent apoptotic response and suggest that it contributes to the activity of multiple anticancer agents.
-
Rotavirus NSP4 and MLKL-Dependent Necroptosis
2026-08-22
The reference study identifies rotavirus non-structural protein 4 (NSP4) as a viral trigger that reorganizes the host RIPK1–RIPK3 necrosome and promotes MLKL-dependent necroptosis. Its mechanistic model links NSP4-mediated endoplasmic reticulum calcium efflux to calcium-dependent RIPK3 recruitment, while showing that RIPK1 functions primarily as a kinase-independent scaffold in this process.
-
OSMI-1: O-GlcNAc Transferase Inhibitor Guide
2026-08-21
OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor with a product-reported IC50 of 2.7 μM. It enables controlled reduction of protein O-GlcNAcylation, but its concentration-dependent cytotoxicity and zebrafish acute-toxicity data require model-specific validation.
-
Cyclic di-GMP for Biofilm and STING Research
2026-08-20
Cyclic di-GMP connects bacterial biofilm persistence research with STING-focused immune modulation research. This practical guide explains how to handle the water-soluble messenger, design stage-aware bacterial assays, and interpret exploratory applications in cancer immunotherapy studies.
-
Deferasirox: Pharmacokinetics and Clinical Evidence
2026-08-20
Galanello, Campus, and Origa synthesized pharmacokinetic, pharmacodynamic, efficacy, and safety evidence for deferasirox across transfusion-dependent anemias. Their review framed Exjade as an oral alternative to infusion-based chelation while emphasizing individualized dosing, laboratory monitoring, and the persistent problem of incomplete response.
-
Phosbind Biotin LC: PVDF Phosphoprotein Detection
2026-08-19
Phosbind Biotin LC is a phosphate-binding reagent for detecting phosphorylated proteins on PVDF membranes without relying on phospho-specific antibody sequence recognition. It is intended for Western Blot workflows with streptavidin-HRP and chemiluminescence, not aqueous-only protocols, water-based preparation, or long-term storage of working solutions.
-
Difloxacin HCl: Assay Workflows and Optimization
2026-08-19
Difloxacin HCl supports two distinct research workflows: bacterial DNA gyrase inhibition measured by antimicrobial susceptibility testing and exploratory multidrug resistance reversal studies based on MRP substrate sensitization. This guide connects formulation, assay design, checkpoint-biology context, and troubleshooting without treating research observations as clinical breakpoints.
-
Ferrostatin-1: Ferroptosis Assay Workflow
2026-08-18
Ferrostatin-1 (Fer-1) provides a practical rescue control for distinguishing lipid-peroxidation-driven cell death from nonspecific toxicity. This guide translates trophoblast ferroptosis findings into reproducible workflows for cancer biology research, neurodegenerative disease models, and oxidative injury studies.
-
LC–MS/MS Mapping of NGP-1 Conversion Pathways
2026-08-18
A January 2026 Microchemical Journal study established an LC–MS/MS workflow to track conversion of the GS-441524 prodrug NGP-1 across gastric, blood, hepatic, and in vivo rat systems. The results indicate that NGP-1 can generate GS441 at multiple sites, providing a mechanistic framework for interpreting oral exposure and GS-441524 pharmacokinetics.
-
Wortmannin for PI3K/AKT Ferroptosis Studies
2026-08-17
Use Wortmannin as a mechanistic PI3K inhibitor to connect FAT4 loss, AKT activation, and ferroptosis resistance in hepatocellular carcinoma models. This guide combines pathway-focused workflows, assay controls, solubility guidance, and troubleshooting for cancer research applications.